Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ICARES MedicusROCO:6612 -2.01%85 5-Year Yield-on-Cost % is 0.51 as of Aug. 24, 2026, which is 39% below its 10-year median of 0.83. GuruFocus rates ROCO:6612 with a GF Score™ of 85/100 and a GF Value™ of NT$173.02 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 315 Medical Devices & Instruments companies, ICARES Medicus ranks worse than 86.03% on this metric.
ICARES Medicus's yield on cost for the quarter that ended in Jun. 2026 was 0.51.
The historical rank and industry rank for ICARES Medicus's 5-Year Yield-on-Cost % or its related term are showing as below:
ROCO:6612'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.14 Med: 0.83 Max: 2.01
Current: 0.51
During the past 13 years, ICARES Medicus's highest Yield on Cost was 2.01. The lowest was 0.14. And the median was 0.83.
ROCO:6612's 5-Year Yield-on-Cost % is ranked worse than 86.03% of 315
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs ROCO:6612: 0.51
ICARES Medicus (ROCO:6612) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
ICARES Medicus 5-Year Yield-on-Cost % Related Terms
ROCO:6612 vs ISRG, BDX, MDLN: 5-Year Yield-on-Cost % Comparison
For the Medical Instruments & Supplies subindustry, ICARES Medicus's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ICARES Medicus 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ICARES Medicus's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where ICARES Medicus's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of ICARES Medicus is calculated as
ICARES Medicus (ROCO:6612) has a 5-Year Yield-on-Cost % of 0.51 as of Aug. 24, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ICARES Medicus and its competitors. This is 39% below median its historical median of 0.83. Over the past decade, ICARES Medicus' 5-Year Yield-on-Cost % has ranged from 0.14 to 2.01. According to the industry distribution chart, ICARES Medicus ranks #271 out of 315 companies in the Medical Devices & Instruments industry, placing it in the top 86%.
Is ICARES Medicus' 5-Year Yield-on-Cost % too high?
ICARES Medicus' current 5-Year Yield-on-Cost % of 0.51 is 39% below median its 10-year median of 0.83. Over the past 10 years, this metric has ranged from a low of 0.14 to a high of 2.01. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. ICARES Medicus' value of 0.51 is 79.2% below this industry median. Based on the distribution chart, ICARES Medicus ranks #271 out of 315 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, ICARES Medicus has a GF Score™ of 85/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ICARES Medicus' 5-Year Yield-on-Cost % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, ICARES Medicus ranks #271 out of 315 companies for 5-Year Yield-on-Cost %. This places ICARES Medicus in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. ICARES Medicus' value of 0.51 is 79.2% below this benchmark. Historically, ICARES Medicus' own 5-Year Yield-on-Cost % has ranged from 0.14 to 2.01 over the past decade. While the company's 10-year median is 0.83 vs. the industry median of 2.45, ICARES Medicus has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 315 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ICARES Medicus's current 5-Year Yield-on-Cost % of 0.51 is 79.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on ICARES Medicus and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ICARES Medicus's current 5-Year Yield-on-Cost % is 0.51, which is 39% below median its own 10-year median of 0.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICARES Medicus stock overvalued right now?
Based on GuruFocus' analysis, ICARES Medicus (ROCO:6612) is currently considered Possible Value Trap. The stock's GF Value™ is NT$173.02, compared to a current price of NT$73.20 — trading 57.7% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.51, which is 39% below median its 10-year median of 0.83 and 79.2% below the Medical Devices & Instruments industry median of 2.45. ICARES Medicus' overall GF Score™ is 85/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For ICARES Medicus (ROCO:6612), the current 5-Year Yield-on-Cost % is 0.51 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ICARES Medicus (ROCO:6612) Overvalued in 2026?
Based on GuruFocus' analysis, ICARES Medicus stock appears to be undervalued.
The current stock price of NT$73.20 is trading 57.7% below its estimated GF Value™ of NT$173.02.
GuruFocus considers ICARES Medicus to be Possible Value Trap.
Key valuation signals for ROCO:6612:
5-Year Yield-on-Cost %: 0.51 (39% below median its 10-year median of 0.83)
GF Value™: NT$173.02 vs. price of NT$73.20 (57.7% below fair value)
Industry Position: 79.2% below the Medical Devices & Instruments median (#271 of 315)
No single metric tells the full story. See the ROCO:6612 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ICARES Medicus Inc is engaged in providing high-grade nanomedical lubricious coatings and various surface treatments for implantable or interventional medical devices. In addition, it also designs, develops, manufactures, and sells intraocular lenses and nanomedical devices. The company's operating segments are Europe and America, which derive maximum revenue, China, and R.O.C. Geographically, it generates maximum revenue from the United States, followed by Taiwan, Spain, England, Japan, China, Germany, and other countries.
85GF Score
Get the complete analysis for ROCO:6612
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6612 has been successfully added to your 
